374930-88-8

Basic information

• Product Name: 5-BROMO-2-(4-BOC-PIPERAZIN-1-YL)PYRIMIDINE
• Synonyms: 5-BROMO-2-(4-BOC-PIPERAZIN-1-YL)PYRIMIDINE;4-(5-BROMOPYRIMIDIN-2-YL)PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;4-(5-BROMOPYRIMIDIN-2-YL)PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER, 95+%;5-Bromo-2-[(N-Boc)piperazin-1-yl]pyrimidine;1-Boc-4-(5-bromopyrimidin-2-yl)piperazine;1-Piperazinecarboxylic acid, 4-(5-bromo-2-pyrimidinyl)-, 1,1-dimethylethyl ester;1-N-Boc-4-(5-broMopyriMidin-2-yl)piperazine;4-(5-bromo-2-pyrimidinyl)-1-piperazinecarboxylic acid tert-butyl ester
• CAS NO: 374930-88-8
• Molecular Formula: C₁₃H₁₉BrN₄O₂
• Molecular Weight: 343.22
• Product Categories: pharmacetical;Organohalides;Pyrimidine
• Mol File: 374930-88-8.mol
• Article Data: 18

Chemical Properties

• Boiling Point: 451°Cat760mmHg
• Flash Point: 226.5°C
• Appearance: /
• Density: 1.414g/cm³
• Vapor Pressure: 2.53E-08mmHg at 25°C
• Refractive Index: 1.562
• Storage Temp.: 2-8°C(protect from light)
• PKA: 3.46±0.42(Predicted)
• CAS DataBase Reference: 5-BROMO-2-(4-BOC-PIPERAZIN-1-YL)PYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-2-(4-BOC-PIPERAZIN-1-YL)PYRIMIDINE(374930-88-8)
• EPA Substance Registry System: 5-BROMO-2-(4-BOC-PIPERAZIN-1-YL)PYRIMIDINE(374930-88-8)

Safety Data

• Hazard Codes: Xi,T
• Statements: 25
• Safety Statements: 45
• RIDADR: UN 2811 6.1 / PGIII
• Hazardous Substances Data: 374930-88-8(Hazardous Substances Data)

Usage

General Description

5-Bromo-2-(4-BOC-piperazin-1-yl)pyrimidine is a chemical compound with the molecular formula C11H16BrN5O2. It is a pyrimidine derivative and contains a bromine atom as well as a piperazine moiety with a BOC (tert-butoxycarbonyl) protecting group. 5-BROMO-2-(4-BOC-PIPERAZIN-1-YL)PYRIMIDINE has potential applications in medicinal chemistry and drug development, as it can be used as a building block in the synthesis of various pharmaceutical compounds. It is a valuable intermediate in the synthesis of novel heterocyclic compounds and may have therapeutic potential in the treatment of certain diseases. Overall, 5-Bromo-2-(4-BOC-piperazin-1-yl)pyrimidine is a versatile chemical building block with potential applications in the pharmaceutical industry.

InChI:InChI=1/C13H19BrN4O2/c1-13(2,3)20-12(19)18-6-4-17(5-7-18)11-15-8-10(14)9-16-11/h8-9H,4-7H2,1-3H3

Upstream product

• 32779-37-6 2,5-dibromopyrimidine 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 32779-36-5 5-Bromo-2-chloropyrimidine 

Downstream Products

• 380382-62-7 N-[((5S)-3-{3-fluoro-4-[2-(1-piperazinyl)-5-pyrimidinyl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide 
• 1188918-36-6 N-({(5S)-3-[3-fluoro-4-(2-{4-[(2-methyl-6-nitro-2,3-dihydro-imidazo[2,1-b][1,3]oxazol-2-yl)methyl]-1-piperazinyl}-5-pyrimidinyl)-phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide 
• 950410-05-6 5-bromo-2-(4-ethylpiperazin-1-yl)pyrimidine 
• 99931-82-5 1-(5-bromopyrimidin-2-yl)piperazine 
• 1283119-60-7 tert-butyl 4-(5-benzylpyrimidin-2-yl)piperazine-1-carboxylate 

Relevant articles and documents

Improvement of Aqueous Solubility of Lapatinib-Derived Analogues: Identification of a Quinolinimine Lead for Human African Trypanosomiasis Drug Development

Lapatinib, an approved epidermal growth factor receptor inhibitor, was explored as a starting point for the synthesis of new hits against Trypanosoma brucei, the causative agent of human African trypanosomiasis (HAT). Previous work culminated in 1 (NEU-1953), which was part of a series typically associated with poor aqueous solubility. In this report, we present various medicinal chemistry strategies that were used to increase the aqueous solubility and improve the physicochemical profile without sacrificing antitrypanosomal potency. To rank trypanocidal hits, a new assay (summarized in a cytocidal effective concentration (CEC50)) was established, as part of the lead selection process. Increasing the sp3 carbon content of 1 resulted in 10e (0.19 μM EC50 against T. brucei and 990 μM aqueous solubility). Further chemical exploration of 10e yielded 22a, a trypanocidal quinolinimine (EC50: 0.013 μM; aqueous solubility: 880 μM; and CEC50: 0.18 μM). Compound 22a reduced parasitemia 109 fold in trypanosome-infected mice; it is an advanced lead for HAT drug development.

POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS

The present invention is related to a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by the following structural formula: The present invention is also related a method of treating a subject with a disease which can be ameliorated by inhibition of poly(ADP-ribose)polymerase (PARP). The definitions of the variables are provided herein.

GLYCOSIDASE INHIBITORS

Compounds of formula (I) wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.